BRAINAURORA-B (06681) announced that its indirect wholly-owned subsidiary, Zhejiang Brainaurora Medical Technology Co., Ltd. ("Zhejiang Brainaurora"), has formally executed a "Cognitive Digital Therapy Project Cooperation Agreement" with Beijing Jianguo Medical Technology Co., Ltd. ("Beijing Jianguo Medical").
From January 1, 2026, to December 30, 2026, the two parties will engage in in-depth collaboration centered on the project "Construction and Promotion of Application Scenarios for Cognitive Function Assessment and Training in Mental Health," aiming to jointly advance the standardization, scaling, and accessibility of digital therapies for cognitive impairment.
This collaboration represents another significant step for the company in the application and ecosystem development of cognitive impairment digital therapies, following its participation in a National Science and Technology Major Project and the approval of a Beijing Key Laboratory for Cognitive Impairment Digital Therapy.
Specifically, this cooperation will: 1. Deepen technological exploration and productization in the mental health field: By partnering with the executing entity of a national-level research center project, the company will delve into the specific application scenario of mental health to explore and validate innovative models for the assessment, training, and management pathways of digital therapy.
This will facilitate the deep integration of cutting-edge artificial intelligence algorithms with actual clinical needs, fostering the development of more precise and universally applicable technological products and expanding the application boundaries of digital therapy in mental health.
2. Promote the establishment of industry standards and market normalization: Participation in national standard research and multi-center sample validation will not only help accumulate high-level evidence-based medical evidence but also enable direct involvement in shaping industry standards.
This will enhance the industry recognition and authority of the company's solutions, laying a solid foundation for the large-scale nationwide promotion of its products.
3. Expand the inclusive service network and social impact: The project focuses on mental health welfare institutions and community settings, aiming to enhance cognitive impairment service capabilities at the grassroots level and within specific organizations.
Successful implementation will significantly broaden the reach of the company's products and services, particularly increasing penetration within the public health and social welfare systems, thereby creating substantial social benefits while opening up new market growth opportunities.
4. Strengthen industry-research collaboration and data asset accumulation: The partnership with Beijing Jianguo Medical further consolidates the company's collaborative network with national-level scientific research institutions.
The real-world data obtained from jointly building long-term research cohorts will become a valuable asset driving the iteration of the company's algorithms, product optimization, and innovative research and development.
Comments